NC
VIR icon

nVerses Capital’s Vir Biotechnology VIR Stock Holding History

nVerses Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,500
Closed -$56.2K – 867
2024
Q3 		$56.2K Buy
+7,500
New +$65.1K 0.03% 602

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

nVerses Capital's VIR Position: Q4 2024 in Review

nVerses Capital sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 7,500 shares — an estimated $56.2K sold.

nVerses Capital first reported a position in VIR in Q3 2024 and held it in 1 quarter. The position peaked at $56.2K in Q3 2024. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • nVerses Capital reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 7,500 Vir Biotechnology shares in Q4 2024, an estimated $56.2K.
  • nVerses Capital first reported a position in Vir Biotechnology in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's Vir Biotechnology position peaked at $56.2K in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.